Overview
Cell and Gene Therapy (CGT) is revolutionizing the treatment of diseases once thought untreatable. For cell-based therapies, maintaining and assessing genomic integrity throughout culture, reprogramming, editing, and differentiation remains a considerable challenge.
Current Challenges
- Effective therapies depend on the thorough detection of variants, which presently requires a combination of advanced tools such as next-generation sequencing (NGS), microarrays, fluorescence in situ hybridization (FISH), and karyotyping.
- While these methods can detect various chromosomal changes and CNVs, emerging evidence suggests that many structural variants (SVs) may go undetected using traditional approaches.
- The widespread adoption of genome engineering technologies like CRISPR has introduced new quality-control challenges, creating unintended structural alterations at both on-target and off-target sites.
The OhmX Solution
The OhmX Platform addresses these critical needs by providing comprehensive structural variant detection from 300 bp to Mb size chromosome changes in a single assay. Unlike traditional methods that require multiple technologies and may still miss key variants, EGM offers unbiased, genome-wide SV detection with the resolution and sensitivity needed for rigorous CGT quality control.
Delivering Confidence and Precision to Genomic SV Discovery
Redefining Genome Integrity Analysis
Unlock unparalleled clarity in genomic characterization with precision that spans structural variants and chromosomal aberrations from 300 bp to several megabases.
Empowering Genome Engineering Excellence
Reveal the unseen—subtle regions influencing CRISPR edits, off-target effects, and unexpected rearrangements—so you can refine strategies and accelerate therapeutic advancement.
End-to-End Support & Accessibility
Cutting-edge technology paired with expert bioinformatics and customer support. Our Reagent Rental Program removes upfront capital barriers.
Simplified Cost Structure
Experience full-spectrum genome integrity analysis at a fraction of the cost of traditional long-read sequencing. Simplified budgeting for confident scaling.
Today’s Power, Tomorrow’s Potential
The OhmX Platform powers breakthroughs across today’s most pressing challenges and tomorrow’s scientific frontiers. By delivering unmatched resolution for structural variant detection, OhmX reveals genomic details ranging from 300 base pairs to several megabases—insights that sequencing-based methods routinely miss. Built for scalability and future evolution, the platform adapts seamlessly from exploratory discovery projects to regulated clinical development, ensuring consistency and reliability at every stage.